Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02436668
Recruitment Status : Completed
First Posted : May 7, 2015
Last Update Posted : August 13, 2019
Sponsor:
Information provided by (Responsible Party):
Pharmacyclics LLC.

Tracking Information
First Submitted Date  ICMJE May 4, 2015
First Posted Date  ICMJE May 7, 2015
Last Update Posted Date August 13, 2019
Study Start Date  ICMJE May 2015
Actual Primary Completion Date October 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 11, 2018)
  • Progression Free Survival (PFS) [ Time Frame: Approximately 3 years after the first subject is randomized. ]
    PFS is defined as the time from the date of randomization until disease progression per RECIST 1.1 criteria assessed by investigator, or death from any cause, whichever occurs first.
  • Overall Survival (OS) [ Time Frame: Approximately 3 years after the first subject is randomized. ]
    OS, is defined as the time from date of randomization until date of death from any cause.
Original Primary Outcome Measures  ICMJE
 (submitted: May 6, 2015)
Progression Free Survival (PFS) [ Time Frame: Approximately 3 years after the first subject is randomized. ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 11, 2018)
  • Number of participants with adverse events as a measure of safety and tolerability of ibrutinib and nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine. [ Time Frame: Up tp 30 days after the last participating subject discontinues study drug ]
  • Overall response rate [ Time Frame: Approximately 3 years after the first subject is randomized. ]
    ORR is defined as the proportion of subjects who achieve a complete response or partial response, based on investigator assessment according to RECIST 1.1.
  • Clinical Benefit Response [ Time Frame: Approximately 3 years after the first subject is randomized. ]
    Subject achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card [MPAC]) or analgesic consumption, or a 20-point or greater improvement in KPS for a period of at least 4 consecutive weeks, without showing any sustained worsening in other parameters. OR Subject was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation (Burris 1997).
  • Carbohydrate Antigen 19-9 (CA19-9) Response [ Time Frame: Approximately 3 years after the first subject is randomized. ]
    CA19-9 response rate is defined as the proportion of subjects with a decline of 20%, 90% and other thresholds considered clinically meaningful, from baseline.
  • Patient-reported outcomes (PRO): global health status based on QLQ-C30 [ Time Frame: Approximately 3 years after the first subject is randomized. ]
    Scores and change from baseline for EORTC QLQ-C30 will be descriptively summarized by treatment group and visit.
  • Rate of venous thromboembolic events (VTE) [ Time Frame: Approximately 3 years after the first subject is randomized. ]
    The VTE rate is defined as proportion of subjects with Venous thromboembolic events (SMQ) per investigator assessment.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 6, 2015)
  • Number of participants with adverse events as a measure of safety and tolerability of ibrutinib and nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine. [ Time Frame: Up tp 30 days after the last participating subject discontinues study drug ]
  • Overall Survival (OS) [ Time Frame: Three years after first subject enrolled ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Official Title  ICMJE A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Brief Summary This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Pancreatic Adenocarcinoma
Intervention  ICMJE
  • Drug: Ibrutinib
    Other Name: IMBRUVICA®
  • Drug: Gemcitabine
  • Drug: Nab-paclitaxel
Study Arms  ICMJE
  • Active Comparator: Ibrutinib

    Ibrutinib daily in combination with:

    Nab-paclitaxel and gemcitabine

    Interventions:
    • Drug: Ibrutinib
    • Drug: Gemcitabine
    • Drug: Nab-paclitaxel
  • Placebo Comparator: Placebo

    Placebo daily in combination with:

    Nab-paclitaxel and gemcitabine

    Interventions:
    • Drug: Gemcitabine
    • Drug: Nab-paclitaxel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 11, 2018)
430
Original Estimated Enrollment  ICMJE
 (submitted: May 6, 2015)
326
Actual Study Completion Date  ICMJE April 25, 2019
Actual Primary Completion Date October 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma.
  2. Stage IV disease diagnosed within 6 weeks of randomization
  3. Adequate hematologic function:

    • Absolute neutrophil count (ANC) ≥1.5 x 109/L
    • Platelet count ≥100 x 109/L
    • Hemoglobin ≥9 g/dL
  4. Adequate hepatic and renal function defined as:

    • AST and/or ALT ≤5.0 x upper limit of normal (ULN) if liver metastases, or ≤3 x ULN without liver metastases
    • Alkaline phosphatase <3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present
    • Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin, such as hemolysis)
    • Estimated Creatinine Clearance ≥30 mL/min
  5. PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN
  6. KPS ≥70.
  7. Eastern Cooperative Oncology Group (ECOG) 0-1

Exclusion Criteria:

  1. Prior therapies: BTK inhibitor, radiotherapy, radiotherapy in the adjuvant setting, or cytotoxic chemotherapy for primary disease of pancreatic adenocarcinoma.
  2. Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
  3. Known brain or leptomeningeal disease (CT or MRI scan of the brain required only in case of clinical suspicion of central nervous system involvement).
  4. Major surgery within 4 weeks of first dose of study drug.
  5. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   France,   Germany,   Italy,   Korea, Republic of,   Spain,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02436668
Other Study ID Numbers  ICMJE PCYC-1137-CA
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pharmacyclics LLC.
Study Sponsor  ICMJE Pharmacyclics LLC.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: George Cole, MD Pharmacyclics LLC.
PRS Account Pharmacyclics LLC.
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP